A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT07231952
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Lymphoplasmacytic Lymphoma
- Waldenstrom Macroglobulinemia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Pirtobrutinib — DRUGPO QD
- Venetoclax — DRUGPO QD
- Rituximab — DRUGIV or SC
Study Details
The purpose of this study is to find out if the combination of pirtobrutinib, venetoclax, and rituximab is an effective treatment for participants with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)
Key Dates
- Start date
- Nov 11, 2025
- Status verified
- Jun 2026
- Primary completion
- Apr 11, 2028
- Completion
- Apr 11, 2028
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Participants with Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)Participants with treatment naive Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Primary Outcome Measure
Number of participants with Very Good Partial Response Rate or Better [ Time Frame: 1 year ]
Central Contacts
- M. Lia Palomba, MD646-608-3711
- Jennifer Lue, MD646-608-4160
Locations (9)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Beth Israel Deaconess Medical Center (Data Collection Only) | Boston | Massachusetts | 02215 | Gottfried von Keudell, MD 617-667-9920 |
| Dana Farber Cancer Institute (Data Collection and Specimen Analysis) | Boston | Massachusetts | 02115 | Jorge Castillo, MD 617-632-4218 |
| Memorial Sloan Kettering Basking Ridge | Basking Ridge | New Jersey | 07920 | M. Lia Palomba, MD 646-608-3711 |
| Memoral Sloan Kettering Monmouth | Middletown | New Jersey | 07748 | M. Lia Palomba, MD 646-608-3711 |
| Memorial Sloan Kettering Bergen | Montvale | New Jersey | 07645 | M Lia Palomba, MD 646-608-3711 |
| Memorial Sloan Kettering Suffolk - Commack | Commack | New York | 11725 | M. Lia Palomba, MD 646-608-3711 |
| Memorial Sloan Kettering Westchester | Harrison | New York | 10604 | M. Lia Palomba, MD 646-608-3711 |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | M. Lia Palomba, MD 646-608-3711 |
| Memorial Sloan Kettering Nassau | Uniondale | New York | 11553 | M. Lia Palomba, MD 646-608-3711 |
Find similar trials in Boston, MA
By research site
Beth Israel Deaconess Medical Center (Data Collection Only)· Boston, MADana Farber Cancer Institute (Data Collection and Specimen Analysis)· Boston, MAMemorial Sloan Kettering Basking Ridge· Basking Ridge, NJMemoral Sloan Kettering Monmouth· Middletown, NJMemorial Sloan Kettering Bergen· Montvale, NJMemorial Sloan Kettering Suffolk - Commack· Commack, NY
Related Studies
- A Long-term Extension Study of PCI-32765 (Ibrutinib)PHASE3 · Recruiting · Janssen Research & Development, LLC · Duarte, California
- Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeRecruiting · Dana-Farber Cancer Institute · Boston, Massachusetts
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaPHASE2 · Recruiting · National Cancer Institute (NCI) · Tucson, Arizona
- Study of SGR-1505 in Mature B-Cell NeoplasmsPHASE1 · Recruiting · Schrödinger, Inc. · Gilbert, Arizona